Funding
Biomedical Diagnostics, an in vitro diagnostics company specialising in auto-immune diseases, has announced a €3 million share capital increase led by Truffle Capital and AGF Private Equity.
“This round of fundraising and the accompanying rationalisation of BMD’s share capital should enable the company to continue to grow its business,” said Philippe Pouletty, acting CEO of BMD and General Partner of Truffle Capital.
“These resources will enable us to accelerate the development of novel products in new indications, notably in the field of resistance to therapeutic monoclonal antibodies and forge new industrial and commercial alliances,” said Denis Fortier, BMD's Chief Operating Officer.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.